Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.1.34.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JD.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.25NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.79NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HP.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FU.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XAGNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.1.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.9.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.1.17NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BN.1.4.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BK.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DJ.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.16NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.1.21NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.32NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.26.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FK.1.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FK.1.2.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FK.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CH.1.1.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
XBB.1.5.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.5.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HD.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HQ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FD.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.2.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FK.1.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FT.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBF.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GJ.1.2.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.1.25NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.76NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-12311.6US
BN.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CK.1.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.4.6.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.75.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.40NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DM.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used